Pharming Group N.V. Logo

Pharming Group N.V.

Develops & commercializes protein & precision medicines for rare, life-threatening diseases.

PHARM | AS

Overview

Corporate Details

ISIN(s):
NL0010391025 (+1 more)
LEI:
724500DCJ9MPG74JEH91
Country:
Netherlands
Address:
Darwinweg 24, 2333CR Leiden
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients with rare, debilitating, and life-threatening diseases. The company's portfolio focuses on protein replacement therapies and precision medicines designed to address significant unmet medical needs. By concentrating on both development and commercialization, Pharming aims to provide transformative therapies to underserved patient populations worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:23
Earnings Release
Pharming Group reports second quarter and first half 2025 financial results and…
Dutch 669.6 KB
2025-07-31 08:23
Earnings Release
Pharming Group reports second quarter and first half 2025 financial results and…
English 589.3 KB
2025-07-31 07:16
Earnings Release
Pharming Group N.V., Halfjaarlijkse financiële verslaggeving
English 589.3 KB
2025-06-24 07:35
Regulatory News Service
Pharming Group to host webcast on findings of a new study published in Cell adv…
Dutch 290.6 KB
2025-06-24 07:35
Regulatory News Service
Pharming Group to host webcast on findings of a new study published in Cell adv…
English 260.5 KB
2025-06-12 07:44
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
Dutch 182.9 KB
2025-06-12 07:44
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
English 176.9 KB
2025-05-01 06:28
Pre-Annual General Meeting Information
Pharming Group announces the 2025 Annual General Meeting of Shareholders and th…
English 182.9 KB
2025-04-23 09:44
Environmental & Social Information
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as…
English 296.9 KB
2025-04-03 07:26
Annual Report (ESEF)
Pharming Group N.V., Jaarlijkse financiële verslaggeving
English 25.3 MB
2025-03-04 15:29
Post-Annual General Meeting Information
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
Dutch 224.7 KB
2025-03-04 15:29
Board/Management Information
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
English 224.4 KB
2025-02-21 07:38
M&A Activity
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 …
Dutch 254.4 KB
2025-02-21 07:38
M&A Activity
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70…
English 284.0 KB
2025-02-10 07:36
M&A Activity
Pharming Technologies B.V. declares unconditional and completes the recommended…
Dutch 272.1 KB

Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharming Group N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-24 D.A. Jorn Non-Executive member Other 7,446 N/A
2023-03-21 P. Sekhri Non-Executive member Other 9,363 N/A
2022-10-27 P. Sekhri Non-Executive member Buy 13,013 12,232.22 EUR
2022-10-27 M. Pykett Non-Executive member Buy 9,760 9,174.40 EUR
2022-08-04 P. Sekhri Non-Executive member Buy 13,013 10,000.23 EUR
2022-08-04 S. Baert Non-Executive member Buy 9,760 7,500.36 EUR
2022-05-25 J. van der Meijs Non-Executive member Buy 9,300 86,490,000.00 EUR
2022-05-25 P. Sekhri Non-Executive member Buy 12,398 9,527.62 EUR
2022-05-25 M. Pykett Non-Executive member Buy 9,300 7,146.86 EUR
2022-03-24 S. de Vries Non-Executive member Buy 318,150 232,249.50 EUR

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.